Jan 13, 2025 08:36AM
Jan 13, 2025 08:30AM
Nov 12, 2024 12:51PM
Nov 12, 2024 08:00AM
Jul 26, 2024 02:51PM
Mar 14, 2024 06:32AM
Feb 28, 2024 04:03PM Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
Jan 8, 2024 08:35AM
Jan 8, 2024 08:30AM
Nov 2, 2023 04:05PM
Oct 17, 2023 04:30PM
Oct 17, 2023 04:30PM
Aug 3, 2023 04:05PM
May 4, 2023 04:02PM Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Sep 30, 2021 12:14PM
Sep 22, 2021 09:49AM
Sep 21, 2021 08:06AM
Sep 21, 2021 08:00AM
Sep 13, 2021 06:47AM
Sep 13, 2021 06:45AM
Sep 10, 2021 05:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2021 05:30PM
Aug 19, 2021 05:32PM
Aug 19, 2021 05:30PM
Aug 10, 2021 07:00PM
Aug 5, 2021 04:02PM
Jul 29, 2021 04:00PM
Jul 26, 2021 08:00PM Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea
Jul 12, 2021 06:00PM
Jun 24, 2021 04:05PM
Jun 23, 2021 09:07AM
Jun 23, 2021 09:00AM
Jun 16, 2021 09:00AM
Jun 10, 2021 05:30PM
Jun 7, 2021 09:02AM Mirum Pharmaceuticals (MIRM) Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors
Jun 7, 2021 09:00AM
Jun 3, 2021 10:10AM
May 26, 2021 09:00AM
May 10, 2021 09:00PM
May 6, 2021 04:05PM
Apr 29, 2021 04:05PM
Apr 29, 2021 08:17AM Mirum Pharmaceuticals (MIRM) and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases
Apr 29, 2021 08:00AM
Apr 29, 2021 08:00AM
Apr 26, 2021 09:03AM
Apr 26, 2021 09:00AM
Apr 12, 2021 05:30PM
Apr 12, 2021 08:01AM
Apr 12, 2021 08:00AM Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
Mar 29, 2021 09:01AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All